Skip to main content
. Author manuscript; available in PMC: 2016 Aug 1.
Published in final edited form as: Nano Today. 2015 Sep 5;10(4):487–510. doi: 10.1016/j.nantod.2015.06.006

Figure 6.

Figure 6

Patients (n=22) injected with CKD-602 (PEGylated liposomal camptothecin analog) were monitored for particle clearance and drug release versus decrease in monocytes over the course of treatment. Increased monocytic activities in cancer patients reduced the area under the curve (AUC, bioavailability), or the amount of circulating nanoparticles in plasma. This MPS effect clearly implicates involvement of host macrophages in the clearance of clinical nanoparticle formulations. Reprinted with permission from [3].